左卡尼汀联合重组人促红细胞生成素治疗肾性贫血  

L-carnitine combined recombinant human erythropoietin treatment of renal anemia

作　　者：陆明 游茂翔 

机构地区：[1]大连市金州区第一人民医院肾内科,辽宁大连116100

出　　处：《中国当代医药》2011年第3期15-16,共2页China Modern Medicine

摘　　要：目的:观察左卡尼汀与重组人促红细胞生成素联合应用治疗肾性贫血患者临床疗效。方法:将62例尿毒症维持性血液透析中的肾性贫血患者随机分成治疗组及对照组,各31例,观察治疗3个月。两组患者都静脉注射重组人促红细胞生成素,每周100～150U/kg。治疗组于血液透析后静脉注射左卡尼汀1.0g,每周3次。结果:治疗组Hb、Hct提升水平显著高于对照组(P<0.05)。结论:对血液透析的肾性贫血患者左卡尼汀能显著提高重组人促红细胞生成素的疗效。Objective：To observe clinical efficacy of L-carnitine combined with recombinant human erythropoietin in treatment of renal anemia.Methods：62 uremia patients in hemodialysis with renal anemia were randomly divided into treatment group and control group,each 31 cases,observation and treatment for 3 months.Two groups of patients were in travenous recombinant human erythropoietin weekly 100～150 U/kg.Treatment group after hemodialysis intravenous L-carnitine 1.0 g,3 times a week.Results：The Hb,Hct increase was significantly higher（P0.05）.Conclusion：L-carnitine in renal anemia patients with hemodialysis can significantly improve recombinant human erythropoietin efficacy

关 键 词：左卡尼汀 重组人促红细胞生成素 肾性贫血 尿毒症 血液透析 

分 类 号：R692.5[医药卫生—泌尿科学]